Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Raises $23M in Public Offering of Shares

NEW YORK (GenomeWeb) – Trovagene said today it has closed a public offering of its common stock that brought in $23 million in gross proceeds. 

The company sold 5,111,110 shares of its shares, including 666,666 shares that were issued when the offering's underwriters exercised their overallotment option in full. The offering price was $4.50 per share, Trovagene said. The firm plans to use net proceeds for R&D, working capital, and other general corporate purposes. 

Piper Jaffray was the sole book-running manager on the offering. Janney Montgomery Scott, Maxim Group, and Cantor Fitzgerald acted as co-managers. 

Trovagene priced the offering last week, saying it anticipated $20 million in gross proceeds. The company had $31.2 million in cash and cash equivalents as of Sept. 30, 2014.  

Trovagene's shares rose 7 percent on the Nasdaq in afternoon trading to $5.17.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.